A California District Court jury has found Gilead Sciences (NASDAQ:GILD) guilty of infringing upon patents co-owned by Merck & Co. (NYSE:MRK) and Ionis Pharmaceuticals (NASDAQ:IONS). The jury awarded Merck and Ionis Pharmaceuticals $200 million for …

Fiduciary Trust Co. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 155,767 …

IFC Holdings Incorporated FL increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 65,219 shares of the biopharmaceutical company …

Gilead Sciences (NASDAQ:GILD) develops and markets innovative medicines for the treatment of several life-threatening diseases such as Hepatitis C and AIDS. The company’s turnover and profits have skyrocketed during the last few years, as a result of the …

Investors should brace for possible gain in Gilead Sciences, Inc. (NASDAQ:GILD) stock as the annual International Liver Conference of the European Association for the Study of the Liver (EASL) draws near. Due to be held this year in Barcelona from April 13 …

Johnson & Johnson is a Dividend Champion with 53 consecutive years of dividend growth. Yes, shares are overvalued but investors shouldn’t worry yet. I examine the historic growth of Johnson & Johnson and value the company through a discounted cash flow …

Johnson & Johnson’s 1Q16 Results Are Coming Soon: What to Expect (Continued from Prior Part) Pharmaceuticals segment Johnson & Johnson’s (JNJ) Pharmaceutical segment consists of the company’s immunology and infectious disease franchises as well as its …

More than 1,000 people are suing Johnson & Johnson Co. and Imerys Talc America, claiming the producers of baby powder failed to warn them of the product’s connection to ovarian cancer, reports Bloomberg Businessweek. The lawsuits draw from 20 studies …

On the negative side, Johnson and Johnson’s revenue dropped across the board from 2014 to 2015. All three of the company’s business segments reported year-over-year sales declines, much of which was tied to currency fluctuations outside of the company’s …

Johnson & Johnson has ramped up its ambitious project to learn how to predict who will develop particular diseases and find therapies to prevent or stop the disease early, when it’s most treatable. Since the health care giant announced its groundbreaking …

First Midwest Bank Trust Division decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 101,894 shares of the biopharmaceutical company’s stock after selling …

In November 2015, Allergan and Pfizer Inc. (NYSE: PFE) came together in a reverse buyout, in which Pfizer would be acquired by Allergan to form the largest pharmaceutical company in the world. As of March 17, 2016, the merger, which is valued at over $160 …

Some April Fools’ Day pranks are fun; others, not so much. Pfizer ($PFE) is unamused by an elaborate prank in which a fake press release was sent to and reported on by the Washington Post. The release, and the story, said the pharma giant was holding the …

Will Pfizer Report Growth in Its 1Q16 Earnings? (Continued from Prior Part) Growth contributors As discussed earlier, Pfizer’s (PFE) 1Q16 growth is expected to stem from its Innovative Pharmaceuticals business and its alliance revenues. A few key …

Roche Holding AG said it’s open to discussing ways to set prices for tumor-fighting treatments in the U.K., signaling that the world’s biggest maker of cancer drugs will seek to avoid a repeat of last year’s heated dispute with authorities over the …

“The cobas® Zika test has been specifically designed utilising the generic cobas omni Utility Channel on the cobas® 6800/8800 Systems. These fully-automated high-volume systems provide solutions for blood services to detect the virus and ensure that …

The Story behind Roche Holding’s Valuation—and What’s Driving It (Continued from Prior Part) Roche’s diagnostic unit In 2015, Roche Holding’s (RHHBY) diagnostics sales grew by 6%, reaching 10.8 billion swiss francs, or about $10.9 billion. Major …

The FDA approval for the first ever blood screening Zika test is good news for Puerto Rico, where local blood collections can resume soon Roche Holding Ltd. ADR (OTCMKTS:RHHBY) has won the final approval from the Food and Drug Administration(FDA) to …

Roche Holding Ltd. (OTCMKTS:RHHBY)‘s stock had its “buy” rating reaffirmed by equities research analysts at Citigroup Inc. in a report issued on Friday, Analyst Ratings Network.com reports. Other institutional investors recently made changes to their …

Thomson ReutersLogo of Swiss drugmaker Novartis is seen at its headquarters in Basel By John Miller ZURICH (Reuters) – Novartis took its campaign to invigorate sluggish sales of its new heart-failure medicine Entresto to a U.S. cardiologists meeting on …

Manning & Napier Advisors raised its position in Novartis AG by 26.2% in the fourth quarter. Manning & Napier Advisors now owns 3,507,436 shares of the company’s stock valued at $301,778,000 after buying an additional 727,330 shares during the last quarter.

Federated Investors Inc. PA reduced its stake in shares of Novartis AG (NYSE:NVS) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,755 shares of the company’s …

Turkish prosecutors have launched an investigation into alleged corruption by Swiss pharmaceutical giant Novartis, the Anatolia news agency said Friday. In February, South Korean law enforcement reportedly seized documents and account books from Novartis …

Amica Pension Fund Board of Trustees held its position in Novartis AG (NYSE:NVS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,605 shares of the company’s stock at …

PNC Financial Services Group Inc. boosted its position in Amgen, Inc. (NASDAQ:AMGN) by 0.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,438,620 shares of the medical …

Buckingham Asset Management LLC reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 7,002 shares of the medical research company’s stock after selling 181 …

Many biotech stocks have taken a beating since last August, and it hasn’t just been smaller players feeling the pain. Shares of two of the biggest biotechs — Amgen (NASDAQ:AMGN) and Celgene (NASDAQ:CELG) — are down 15% and 23%, respectively. There’s a …

Amgen, Inc. (NASDAQ:AMGN)‘s stock had its “overweight” rating reissued by Morgan Stanley in a research note issued on Tuesday, Analyst Ratings Network.com reports. They presently have a $193.00 target price on the medical research company’s stock.

Will Amgen’s Blockbuster Drugs and Clinical Trials Drive Growth? (Continued from Prior Part) Oncology research programs Expanded indications and increasing market penetration are expected to drive the growth of Amgen’s oncology portfolio in 2016.

Pictet North America Advisors SA increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 17.8% during the fourth quarter, Holdings Channel reports. The fund owned 31,935 shares of the company’s stock after buying an additional 4,814 shares …

Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (Symbol: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the …

TO: All persons and entities who, from May 21, 1999, through October 29, 2004, inclusive (the “Settlement Class Period”), purchased or otherwise acquired the common stock of Merck & Co., Inc. (“Merck Common Stock”) or call options on Merck Common Stock …

Merck & Co., Inc. (NYSE:MRK) traded up 0.85% during midday trading on Tuesday, reaching $53.28. 4,623,901 shares of the company’s stock were exchanged. The stock has a market cap of $147.87 billion and a P/E ratio of 34.15. The firm’s 50-day moving …

A jury in Northern California has weighed in and decided that Gilead Sciences’ (NASDAQ:GILD) mega-blockbuster drugs Sovaldi and Harvoni violate two patents co-owned by Merck & Co (NYSE:MRK) and Ionis Pharmaceuticals (NASDAQ:IONS). However, the $200 million …

South Dakota Investment Council continued to hold its stake in shares of Sanofi SA (NYSE:SNY) during the fourth quarter, according to its most recent filing with the SEC. The firm owned 27,327 shares of the company’s stock at the end of the fourth quarter.

Regeneron ($REGN) and Sanofi ($SNY) have rung up stellar late-stage data from a pair of large Phase III studies of the blockbuster antibody contender dupilumab, putting it on a straight path to the FDA. Tapped by a number of analysts as one of the biggest …

The launch of Zentiva in Nigeria, the third largest and fastest growing generics company in Europe, by Sanofi, is seen as a move to ameliorate the plight of many, for whom affordable healthcare was out of reach. Writes Mary Ekah Records abound of …

Amica Mutual Insurance Co. continued to hold its position in Sanofi SA (NYSE:SNY) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,892 shares of the company’s …

Regeneron Pharmaceuticals Inc. and Sanofi SA said their experimental drug for a debilitating skin condition called atopic dermatitis met all of its major treatment targets in two late-stage studies, a key step in advancing a potential blockbuster medicine …

Traders sold shares of AbbVie Inc (NASDAQ:ABBV) on strength during trading on Friday, Market Beat Ratings reports. $41.56 million flowed into the stock on the tick-up and $88.98 million flowed out of the stock on the tick-down, for a money net flow of $47 …

Investors have made a lot of money from Big Pharma stocks over the past few years. Two of the biggest winners have quite different backgrounds. AbbVie (NYSE:ABBV) is a spin-off less than four years old. Johnson & Johnson (NYSE:JNJ) has been around since …

Hendershot Investments Inc. raised its position in AbbVie Inc (NASDAQ:ABBV) by 13.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 138,288 shares of the company’s stock after buying an additional …

AbbVie Inc (NASDAQ:ABBV) has earned an “A-” credit rating from analysts at Morningstar. The research firm’s “A-” rating indicates that the company is a low default risk. They also gave their stock a four star rating. Shares of AbbVie (NASDAQ:ABBV …

AbbVie is the maker of the top-selling drug in the world, Humira. Although the composition patent for Humira expires this year, there are still dozens more. The stock remains undervalued following the big selloff in October of last year. AbbVie (NYSE:ABBV …